While few studies in CML patients are available to assess the clinical efficacy of asparaginase (88–91), preclinical studies indicate that asparaginase may also be beneficial for CML treatment (92, 93). The gene discussed is ASPG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.